Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The human monoclonal antibody denosumab ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

The researchers found that with denosumab vs oral bisphosphonates, the risk for emergently treated hypocalcemia increased with worsening CKD stage. (HealthDay News) — For patients with chronic kidney ...

Denosumab and bisphosphonates exhibit similar efficacy and safety profiles for preventing fractures among patients with osteoporosis. Evidence from a large population-based cohort study in South Korea ...

Among 1,032 Japanese patients on dialysis who started treatment for osteoporosis, denosumab use had a 45% lower risk for a composite of all fractures compared with oral bisphosphonates over 3 years ...

Based on the results of a non-inferiority study, in January 2018 the U.S. Food and Drug Administration (FDA) approved the use of denosumab for the prevention of skeletal events in patients with ...

Madrid, Spain, 13 June 2019: The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) finds the risk of bone mineral density (BMD) loss after denosumab ...

LOS ANGELES, Jan 24 (Reuters) - Amgen Inc said on Thursday that a head-to-head trial comparing its experimental osteoporosis drug denosumab to Merck & Co Inc's Fosamax in post-menopausal women with ...

Older women who received denosumab (Prolia, Amgen) for up to 10 years for osteoporosis had a low risk of osteonecrosis of the jaw (ONJ), although the risk was higher — albeit still quite small — if ...